The STARS (Stereotactic Radiosurgery vs. Surgery) trial will compare the three-year survival rate of patients who undergo a lobectomy, a surgical procedure to remove the tumor, versus CyberKnife treatment, a unique stereotactic body radiotherapy technique that precisely tracks and focuses the radiation on the tumor.

这项名为STARS(Stereotactic Radiosurgery vs. Surgery)的研究项目即立体定向放射治疗与外科手术进行比较肺叶切除术和CyberKnife治疗的3年生存率，CyberKnife是一个独特的立体定向放射治疗技术，可以精确定位并和靶向照射对肿瘤。

"Surgery is the current gold standard treatment for Stage I NSCLC. However, there are research reports that describe similar survival rates of operable patients treated with the CyberKnife," said John Dombrowski, MD, Ph.D., assistant professor of radiation oncology at Saint Louis University School of Medicine.

“外科手术是目前治疗I期非小细胞肺癌的金标准。然而部分研究报告显示：外科手术同CyberKnife治疗的三年生存率类似。”美国圣路易斯大学医学院放射肿瘤的助理教授John Dombrowski 博士介绍说。